{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:51:24Z","timestamp":1770749484018,"version":"3.50.0"},"reference-count":147,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"am","delay-in-days":426,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["K23 DK117014"],"award-info":[{"award-number":["K23 DK117014"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1053\/j.akdh.2023.04.003","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T03:22:32Z","timestamp":1693365752000},"page":"343-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Management of Hepatitis C Virus and Hepatitis B Virus Infection in the Setting of Kidney Disease"],"prefix":"10.1053","volume":"30","author":[{"given":"Purva","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rani","family":"Sawtell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4959-7437","authenticated-orcid":false,"given":"Qiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-9713","authenticated-orcid":false,"given":"Meghan E.","family":"Sise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib2","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/ki.1989.84","article-title":"Renal involvement in essential mixed cryoglobulinemia","volume":"35","author":"D'Amico","year":"1989","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00005792-200107000-00004","article-title":"Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center","volume":"80","author":"Trejo","year":"2001","journal-title":"Medicine (Baltim)"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.003_bib4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1046\/j.1365-2893.2000.00204.x","article-title":"Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C","volume":"7","author":"Cicardi","year":"2000","journal-title":"J Viral Hepat"},{"issue":"Suppl 8","key":"10.1053\/j.akdh.2023.04.003_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ndt\/15.suppl_8.28","article-title":"Glomerular disease associated with hepatitis C virus infection in native kidneys","volume":"15","author":"Pouteil-Noble","year":"2000","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ki.1988.152","article-title":"Identification of glomerular immune deposits in cryoglobulinemia glomerulonephritis","volume":"34","author":"Sinico","year":"1988","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.003_bib7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1046\/j.1523-1755.1998.00028.x","article-title":"Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis","volume":"54","author":"D'Amico","year":"1998","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib8","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1681\/ASN.V114690","article-title":"High prevalence and adverse effect of hepatitis C virus infection in type II diabetic-related nephropathy","volume":"11","author":"Soma","year":"2000","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.003_bib9","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.27664","article-title":"Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans","volume":"61","author":"Molnar","year":"2015","journal-title":"Hepatology"},{"issue":"14","key":"10.1053\/j.akdh.2023.04.003_bib10","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1097\/QAD.0b013e32830e0152","article-title":"The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis","volume":"22","author":"Wyatt","year":"2008","journal-title":"Aids"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.kint.2019.04.030","article-title":"Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease","volume":"97","author":"Sise","year":"2020","journal-title":"Kidney Int"},{"issue":"20","key":"10.1053\/j.akdh.2023.04.003_bib12","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 Weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.akdh.2023.04.003_bib13","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for Previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib15","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J Hepatol"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.003_bib16","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/liv.14320","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection","volume":"40","author":"Lawitz","year":"2020","journal-title":"Liver Int"},{"issue":"10003","key":"10.1053\/j.akdh.2023.04.003_bib17","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"issue":"15","key":"10.1053\/j.akdh.2023.04.003_bib18","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.akdh.2023.04.003_bib19","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/apt.16830","article-title":"Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment","volume":"55","author":"Sulkowski","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.003_bib20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1159\/000521298","article-title":"Hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C","volume":"40","author":"Toka","year":"2022","journal-title":"Dig Dis"},{"issue":"12","key":"10.1053\/j.akdh.2023.04.003_bib21","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3390\/jpm12121957","article-title":"Direct-acting antivirals and the risk of hepatitis B reactivation in hepatitis B and C Co-infected patients: a systematic review and meta-analysis","volume":"12","author":"Oh","year":"2022","journal-title":"J Pers Med"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib22","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.kint.2018.06.011","article-title":"Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management","volume":"94","author":"Jadoul","year":"2018","journal-title":"Kidney Int"},{"issue":"109","key":"10.1053\/j.akdh.2023.04.003_bib23","first-page":"S1","article-title":"KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","year":"2008","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.gastro.2017.03.006","article-title":"Efficacy and safety of sofosbuvir plus Daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis","volume":"153","author":"Saadoun","year":"2017","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1053\/j.akdh.2023.04.003_bib25","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/ajg.2017.49","article-title":"Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia","volume":"112","author":"Emery","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cgh.2016.09.158","article-title":"Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals","volume":"15","author":"Bonacci","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1053\/j.akdh.2023.04.003_bib27","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2174\/1389450117666160208145432","article-title":"Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: Preliminary results of a prospective Pilot study","volume":"18","author":"Gragnani","year":"2017","journal-title":"Curr Drug Targets"},{"issue":"10","key":"10.1053\/j.akdh.2023.04.003_bib28","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/annrheumdis-2015-208339","article-title":"Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study","volume":"75","author":"Saadoun","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1053\/j.akdh.2023.04.003_bib29","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1053\/j.gastro.2017.02.037","article-title":"Direct-acting antiviral therapy Restores immune tolerance to patients with hepatitis C virus-induced cryoglobulinemia vasculitis","volume":"152","author":"Comarmond","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.003_bib30","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.28753","article-title":"Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia","volume":"64","author":"Gragnani","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.003_bib31","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.28297","article-title":"Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents","volume":"63","author":"Sise","year":"2016","journal-title":"Hepatology"},{"issue":"11","key":"10.1053\/j.akdh.2023.04.003_bib32","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/rheumatology\/kew268","article-title":"Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy","volume":"55","author":"Sollima","year":"2016","journal-title":"Rheumatology"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib33","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.dld.2017.01.068","article-title":"Direct acting antiviral (DAA) therapy of HCV, effects on the cryoglobulinemic vasculitis: a multi center open label study","volume":"49","author":"Mauro","year":"2017","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib34","doi-asserted-by":"crossref","first-page":"S505","DOI":"10.1016\/S0168-8278(17)31410-1","article-title":"Sofosbuvir\/Ribavirin treatment in patients with genotype 2, Hepatitis C Virus infection and symptomatic mixed cryoglobulinemia: an interim analysis on safety, efficacy and impact on quality of life","volume":"66","author":"Cerretelli","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib35","doi-asserted-by":"crossref","first-page":"S528","DOI":"10.1016\/S0168-8278(17)31459-9","article-title":"Benefit of direct-acting antiviral therapy in hepatitis C virus (HCV) monoinfected and HIV-HCV coinfected patients with mixed cryoglobulinemia","volume":"66","author":"Diakite","year":"2017","journal-title":"J Hepatol"},{"key":"10.1053\/j.akdh.2023.04.003_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820942617","article-title":"Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals","volume":"13","author":"Comarmond","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-Mineral and Bone disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.003_bib38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2009-10-245878","article-title":"Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study","volume":"116","author":"Dammacco","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.akdh.2023.04.003_bib39","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/rheumatology\/kel004","article-title":"Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids","volume":"45","author":"Quartuccio","year":"2006","journal-title":"Rheumatology"},{"issue":"12","key":"10.1053\/j.akdh.2023.04.003_bib40","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1093\/ndt\/gfh469","article-title":"Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis","volume":"19","author":"Roccatello","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1053\/j.akdh.2023.04.003_bib41","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1080\/1042819031000119235","article-title":"Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases","volume":"44","author":"Zaja","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1053\/j.akdh.2023.04.003_bib42","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","article-title":"Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20","volume":"101","author":"Sansonno","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.akdh.2023.04.003_bib43","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/ard.2007.081653","article-title":"Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis","volume":"67","author":"Saadoun","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.003_bib44","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.003_bib45","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/art.34322","article-title":"A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis","volume":"64","author":"Sneller","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.003_bib46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.semarthrit.2006.08.005","article-title":"Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases","volume":"36","author":"Ramos-Casals","year":"2006","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.003_bib47","first-page":"1164","article-title":"Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus","volume":"32","author":"Levine","year":"2005","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.003_bib48","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.gastro.2018.04.024","article-title":"Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure","volume":"155","author":"Bonacci","year":"2018","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.003_bib49","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/ckj\/sfz178","article-title":"Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study","volume":"14","author":"P\u00e9rez de Jos\u00e9","year":"2021","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000493807","article-title":"Incidence and characteristics of de novo Renal Cryoglobulinemia after Direct-Acting Antivirals Treatment in an Egyptian Hepatitis C Cohort","volume":"140","author":"Fayed","year":"2018","journal-title":"Nephron"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib51","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/jcm11040984","article-title":"Persistence of cryoglobulinemic vasculitis after DAA induced HCV cure","volume":"11","author":"Danishwar","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib52","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/archinte.165.1.101","article-title":"Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus\u2013related symptomatic mixed cryoglobulinemias","volume":"165","author":"Monti","year":"2005","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.003_bib53","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hep.29125","article-title":"Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infection","volume":"66","author":"Hogan","year":"2017","journal-title":"Hepatology"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.003_bib54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ekir.2016.06.006","article-title":"Lupus-like immune Complex-mediated glomerulonephritis in patients with hepatitis C virus infection treated with oral, interferon-free, direct-acting antiviral therapy","volume":"1","author":"Sise","year":"2016","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib55","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ajg.2015.391","article-title":"Harvoni (Ledipasvir with Sofosbuvir)-induced renal injury","volume":"111","author":"Wanchoo","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib56","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.14309\/crj.2017.84","article-title":"Acute interstitial nephritis associated with sofosbuvir and Daclatasvir","volume":"4","author":"Ashraf","year":"2017","journal-title":"ACG Case Rep J"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib57","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/14656566.2014.857656","article-title":"Sofosbuvir for the treatment of hepatitis C virus","volume":"15","author":"Asselah","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.003_bib58","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12985-019-1140-x","article-title":"Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2019","journal-title":"Virol J"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.003_bib60","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jceh.2019.10.004","article-title":"Sofosbuvir-velpatasvir Fixed drug combination for the treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney transplantation","volume":"10","author":"Gaur","year":"2020","journal-title":"J Clin Exp Hepatol"},{"issue":"10","key":"10.1053\/j.akdh.2023.04.003_bib61","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2215\/CJN.02510317","article-title":"Effect of sofosbuvir-based hepatitis C virus therapy on kidney function in patients with CKD","volume":"12","author":"Sise","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.003_bib62","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2215\/CJN.07940716","article-title":"Mortality, Hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis","volume":"12","author":"Goodkin","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib63","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.kint.2018.11.038","article-title":"Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients","volume":"95","author":"Jadoul","year":"2019","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.003_bib64","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000355615","article-title":"Hepatitis C infection is very rarely treated among hemodialysis patients","volume":"38","author":"Goodkin","year":"2013","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.003_bib65","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/jhep.2001.26371","article-title":"A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C","volume":"34","author":"Lindsay","year":"2001","journal-title":"Hepatology"},{"issue":"22","key":"10.1053\/j.akdh.2023.04.003_bib66","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","article-title":"Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial","volume":"321","author":"Davis","year":"1989","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1053\/j.akdh.2023.04.003_bib67","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"9286","key":"10.1053\/j.akdh.2023.04.003_bib68","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1053\/j.akdh.2023.04.003_bib69","author":"Guidance"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.003_bib70","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jhep.2017.12.003","article-title":"Higher risk of renal disease in chronic hepatitis C patients: antiviral therapy survival benefit in patients on hemodialysis","volume":"68","author":"S\u00f6derholm","year":"2018","journal-title":"J Hepatol"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.003_bib72","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.kint.2017.10.024","article-title":"Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient","volume":"93","author":"Chute","year":"2018","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.003_bib73","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/j.1600-6143.2005.00864.x","article-title":"Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1053\/j.akdh.2023.04.003_bib74","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ki.2011.194","article-title":"Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy","volume":"80","author":"Baid-Agrawal","year":"2011","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.akdh.2023.04.003_bib75","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1111\/j.1600-6143.2005.01040.x","article-title":"Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.003_bib76","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/jmv.23919","article-title":"Treatment of hepatitis C after kidney transplant: a pooled analysis of observational studies","volume":"86","author":"Fabrizi","year":"2014","journal-title":"J Med Virol"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090611","article-title":"Interferon-based anti-viral therapy for hepatitis C virus infection after renal transplantation: an updated meta-analysis","volume":"9","author":"Wei","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.003_bib78","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","article-title":"Treatment with Ledipasvir-sofosbuvir for 12 or 24 Weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial","volume":"166","author":"Colombo","year":"2017","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib79","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.30046","article-title":"Glecaprevir\/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection","volume":"68","author":"Reau","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.003_bib80","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000486516","article-title":"Effect of the opioid crisis on the donor pool for kidney transplantation: an analysis of national kidney Deceased donor Trends from 2010-2016","volume":"47","author":"Chute","year":"2018","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib81","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMp1505074","article-title":"Transplanting hepatitis C-positive kidneys","volume":"373","author":"Reese","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.003_bib82","doi-asserted-by":"crossref","first-page":"61","DOI":"10.15585\/mmwr.mm6803a2","article-title":"Characteristics of Deceased solid organ donors and screening results for hepatitis B, C, and human Immunodeficiency Viruses - United States, 2010-2017","volume":"68","author":"Abara","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"10.1053\/j.akdh.2023.04.003_bib83","doi-asserted-by":"crossref","first-page":"702","DOI":"10.7326\/M17-2451","article-title":"The drug Overdose epidemic and Deceased-donor transplantation in the United States: a national registry study","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1053\/j.akdh.2023.04.003_bib84","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1111\/ajt.13971","article-title":"Improving organ utilization to help overcome the Tragedies of the opioid epidemic","volume":"16","author":"Goldberg","year":"2016","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.003_bib85","first-page":"10","article-title":"Losing Our Way: Caring for patients who may, Too Soon, Become organ donors","volume":"104","author":"Taylor","year":"2021","journal-title":"R I Med J"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.003_bib86","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/hep.31551","article-title":"Prospective multicenter study of early antiviral therapy in liver and kidney transplant recipients of HCV-viremic donors","volume":"73","author":"Terrault","year":"2020","journal-title":"Hepatology"},{"issue":"7","key":"10.1053\/j.akdh.2023.04.003_bib87","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S2468-1253(20)30081-9","article-title":"Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study","volume":"5","author":"Feld","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1053\/j.akdh.2023.04.003_bib88","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1111\/ajt.15530","article-title":"Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: single center experience","volume":"19","author":"Molnar","year":"2019","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib89","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M20-1468","article-title":"Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis C-negative recipients: an open-label nonrandomized study","volume":"174","author":"Durand","year":"2021","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1053\/j.akdh.2023.04.003_bib90","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1681\/ASN.2020050686","article-title":"Multicenter study to transplant hepatitis C-infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from Deceased donors with hepatitis C virus infection","volume":"31","author":"Sise","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib91","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ekir.2020.01.001","article-title":"Preemptive treatment with elbasvir and grazoprevir for hepatitis C-viremic donor to uninfected recipient kidney transplantation","volume":"5","author":"Sise","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"8","key":"10.1053\/j.akdh.2023.04.003_bib92","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to Noninfected recipients: an open-label nonrandomized trial","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.003_bib93","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial","volume":"169","author":"Reese","year":"2018","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1053\/j.akdh.2023.04.003_bib94","first-page":"1105","article-title":"Transplanting HCV-infected kidneys into uninfected recipients","volume":"377","author":"Goldberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.akdh.2023.04.003_bib95","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1681\/ASN.2019050462","article-title":"National Trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys","volume":"30","author":"Potluri","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.akdh.2023.04.003_bib96","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1097\/TP.0000000000002323","article-title":"Changes in utilization and discard of HCV antibody-positive Deceased donor kidneys in the era of direct-acting antiviral therapy","volume":"102","author":"Bowring","year":"2018","journal-title":"Transplantation"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.003_bib97","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.kint.2022.07.012","article-title":"Executive summary of the KDIGO 2022 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","volume":"102","author":"Martin","year":"2022","journal-title":"Kidney Int"},{"issue":"22","key":"10.1053\/j.akdh.2023.04.003_bib99","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM200205303462202","article-title":"Chronic hepatitis B","volume":"346","author":"Lok","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.akdh.2023.04.003_bib100","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2215\/CJN.09180816","article-title":"Viral-associated GN: hepatitis B and other viral infections","volume":"12","author":"Kupin","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.003_bib101","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3748\/wjg.v16.i6.770","article-title":"Treatment of hepatitis B virus-associated glomerulonephritis: a meta-analysis","volume":"16","author":"Zhang","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"21","key":"10.1053\/j.akdh.2023.04.003_bib102","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199105233242103","article-title":"Membranous nephropathy related to hepatitis B virus in adults","volume":"324","author":"Lai","year":"1991","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib103","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/j.1523-1755.2005.00591.x","article-title":"Lamivudine in hepatitis B-associated membranous nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.003_bib104","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/nep.12795","article-title":"Clinical and morphologic spectrum of renal involvement in patients with HBV-associated cryoglobulinaemia","volume":"22","author":"Li","year":"2017","journal-title":"Nephrology"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.003_bib105","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.md.0000180792.80212.5e","article-title":"Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients","volume":"84","author":"Guillevin","year":"2005","journal-title":"Medicine (Baltim)"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib107","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.003_bib108","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/ki.2013.249","article-title":"Treatment of hepatitis B in patients with chronic kidney disease","volume":"84","author":"Pipili","year":"2013","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.003_bib109","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/039139881003300601","article-title":"Therapy with nucleos(t)ide analogues: current Role in dialysis patients","volume":"33","author":"Fabrizi","year":"2010","journal-title":"Int J Artif Organs"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.003_bib110","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.dld.2006.12.017","article-title":"Prophylaxis and treatment of hepatitis B in immunocompromised patients","volume":"39","author":"Marzano","year":"2007","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.003_bib111","doi-asserted-by":"crossref","first-page":"479","DOI":"10.7326\/0003-4819-111-6-479","article-title":"Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon","volume":"111","author":"Lisker-Melman","year":"1989","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.003_bib112","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1365-2036.2006.03041.x","article-title":"Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis","volume":"24","author":"FABRIZI","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib113","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3904\/kjim.2012.27.4.411","article-title":"Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains","volume":"27","author":"Sun","year":"2012","journal-title":"Korean J Intern Med"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib114","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5414\/CN108648","article-title":"Meta-analysis of the efficacy and safety of nucleotide\/nucleoside analog monotherapy for hepatitis B virus-associated glomerulonephritis","volume":"85","author":"Wang","year":"2016","journal-title":"Clin Nephrol"},{"issue":"8","key":"10.1053\/j.akdh.2023.04.003_bib115","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3748\/wjg.v18.i8.821","article-title":"Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis","volume":"18","author":"Zheng","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.003_bib116","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0168-8278(98)80333-4","article-title":"Successful treatment of polyarteritis nodosa related to hepatitis B virus with interferon alpha as first-line therapy","volume":"28","author":"Av\u015far","year":"1998","journal-title":"J Hepatol"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib117","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0168-8278(97)80263-2","article-title":"Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b","volume":"26","author":"Kruger","year":"1997","journal-title":"J Hepatol"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.003_bib118","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00004836-199504000-00026","article-title":"Successful treatment of hepatitis B virus-associated polyarteritis nodosa by interferon alpha alone","volume":"20","author":"Simsek","year":"1995","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib119","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"issue":"16","key":"10.1053\/j.akdh.2023.04.003_bib120","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1001\/jama.2013.281115","article-title":"FDA: increased HBV reactivation risk with ofatumumab or rituximab","volume":"310","author":"Mitka","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib121","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/apt.12538","article-title":"Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease","volume":"39","author":"Pipili","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"6476","key":"10.1053\/j.akdh.2023.04.003_bib122","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/bmj.290.6476.1180","article-title":"Nephrotic syndrome during treatment with interferon","volume":"290","author":"Selby","year":"1985","journal-title":"Br Med J"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib123","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2215\/CJN.07311009","article-title":"Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis","volume":"5","author":"Markowitz","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib124","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00005792-200207000-00008","article-title":"Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature","volume":"81","author":"Zuber","year":"2002","journal-title":"Medicine (Baltim)"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.003_bib125","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1665-2681(19)31565-0","article-title":"The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: a systematic review and meta-analysis","volume":"10","author":"Yi","year":"2011","journal-title":"Ann Hepatol"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib126","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2013.09.031","article-title":"Telbivudine improves renal function in patients with chronic hepatitis B","volume":"146","author":"Gane","year":"2014","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1053\/j.akdh.2023.04.003_bib127","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2893.2012.01600.x","article-title":"Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-na\u00efve patients with HBV-related decompensated cirrhosis","volume":"19","author":"Chan","year":"2012","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.003_bib128","doi-asserted-by":"crossref","first-page":"e54279","DOI":"10.1371\/journal.pone.0054279","article-title":"52-Week efficacy and safety of telbivudine with Conditional tenofovir Intensification at Week 24 in HBeAg-positive chronic hepatitis B","volume":"8","author":"Piratvisuth","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.003_bib129","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.003_bib130","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib131","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/sj.ki.5000171","article-title":"Long-term lamivudine therapy in hepatitis B-associated membranous nephropathy?","volume":"69","author":"Ng","year":"2006","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.003_bib132","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2215\/CJN.00950208","article-title":"Aspects of immune dysfunction in end-stage renal disease","volume":"3","author":"Kato","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.akdh.2023.04.003_bib133","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3748\/wjg.v17.i12.1563","article-title":"Management of occult hepatitis B virus infection: an update for the clinician","volume":"17","author":"Lled\u00f3","year":"2011","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.003_bib134","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/eri.10.47","article-title":"Preventing infections in patients undergoing hemodialysis","volume":"8","author":"Kallen","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.003_bib135","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1053\/j.ajkd.2003.08.019","article-title":"Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better","volume":"42","author":"DaRoza","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib136","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5414\/CNP68228","article-title":"Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination","volume":"68","author":"Tsouchnikas","year":"2007","journal-title":"Clin Nephrol"},{"issue":"Suppl 3","key":"10.1053\/j.akdh.2023.04.003_bib137","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.003_bib138","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jhep.2012.02.020","article-title":"Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection","volume":"57","author":"Cosconea","year":"2012","journal-title":"J Hepatol"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.003_bib139","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5414\/CN107565","article-title":"Long-term outcome of Hepatitis B-positive renal allograft recipients after development of antiviral treatment","volume":"78","author":"Park","year":"2012","journal-title":"Clin Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.003_bib140","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/TP.0b013e3181e5b811","article-title":"Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments","volume":"90","author":"Yap","year":"2010","journal-title":"Transplantation"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.003_bib141","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1525-139X.2010.00809.x","article-title":"Evaluation of adult kidney transplant candidates","volume":"23","author":"Pham","year":"2010","journal-title":"Semin Dial"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.003_bib142","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00007890-200102150-00008","article-title":"Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence","volume":"71","author":"Han","year":"2001","journal-title":"Transplantation"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.003_bib143","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V100.2.391","article-title":"Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers","volume":"100","author":"Shibolet","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.akdh.2023.04.003_bib144","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/00007890-199810150-00012","article-title":"Reactivation of hepatitis B after transplantation IN patients with pre-EXISTING anti-hepatitis B surface antigen ANTIBODIES: report on three cases and review of the literature","volume":"66","author":"Blanpain","year":"1998","journal-title":"Transplantation"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.003_bib145","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/00007890-199708150-00011","article-title":"Risks of transplanting kidneys from hepatitis B surface antigen-negative, hepatitis B core antibody-positive DONORS1,2","volume":"64","author":"Satterthwaite","year":"1997","journal-title":"Transplantation"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.003_bib146","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1399-3062.2012.00782.x","article-title":"Renal grafts from anti-hepatitis B core-positive donors: a quantitative review of the literature","volume":"14","author":"Mahboobi","year":"2012","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib147","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.transproceed.2011.01.155","article-title":"Kidney transplantation from hepatitis B virus core antibody\u2013positive donors: prophylaxis with hepatitis B immunoglobulin","volume":"43","author":"Veroux","year":"2011","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.003_bib148","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/ajt.13187","article-title":"Solid organ transplantation from hepatitis B virus\u2013positive donors: consensus guidelines for recipient management","volume":"15","author":"Huprikar","year":"2015","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.003_bib149","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1432-2277.2006.00427.x","article-title":"Hepatitis B virus reactivation after renal transplantation: report of two cases","volume":"20","author":"Savas","year":"2007","journal-title":"Transpl Int"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.003_bib150","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.ajkd.2012.08.046","article-title":"Successful kidney transplantation from a hepatitis B surface antigen\u2013positive donor to an antigen-negative recipient using a novel vaccination regimen","volume":"61","author":"Singh","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.akdh.2023.04.003_bib151","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/ajt.12921","article-title":"The outcomes of kidney transplantation in hepatitis B surface antigen (HBsAg)\u2013Negative recipients receiving graft from HBsAg-positive donors: a Retrospective, Propensity Score-matched study","volume":"14","author":"Chancharoenthana","year":"2014","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1053\/j.akdh.2023.04.003_bib152","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/j.1600-6143.2009.02707.x","article-title":"Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center","volume":"9","author":"Jiang","year":"2009","journal-title":"Am J Transplant"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813923000538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813923000538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:39:21Z","timestamp":1757432361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813923000538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":147,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2949813923000538"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2023.04.003","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Hepatitis C Virus and Hepatitis B Virus Infection in the Setting of Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2023.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}